This site is intended for healthcare professionals
Blue, green and purple abstract wave
Drug information

Calamine Lotion BP

OTC
Read time: 2 mins
Last updated: 21 Nov 2016
...
 

Summary of product characteristics


1. Name of the medicinal product

Calamine Lotion BP


2. Qualitative and quantitative composition

Calamine

 15.0% w/v

Zinc Oxide

 5.0% w/v

For the full list of excipients, see section 6.1.


3. Pharmaceutical form

Lotion


4.1. Therapeutic indications

For relief of the symptoms of mild sunburn and other minor skin conditions.


4.2. Posology and method of administration

Topical. Applied directly to the skin.

Recommended dose and dosage schedule

The product is suitable for use by adults, children and the elderly. Apply gently with a pad of cotton wool to the affected parts as required.


4.3. Contraindications

Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1.


4.4. Special warnings and precautions for use

Shake the bottle.For external use only.Keep all medicines away from children.


4.5. Interaction with other medicinal products and other forms of interaction

May mask x-ray pictures under certain circumstances.


4.6. Fertility, pregnancy and lactation

No evidence has been found as to the safety of the product when used during pregnancy and lactation. However, the product has been used for many years without any apparent ill effects.


4.7. Effects on ability to drive and use machines

None known.


4.8. Undesirable effects

Occasional hypersensitivity or irritant reactions.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.


4.9. Overdose

Overdose is considered unlikely with this product. However, if large quantities have been ingested, vomiting, inflammation of mucous membranes of the mouth and stomach, weakness, mental confusion, cold sweats, depression of pulse and leg cramps may occur.Where phenol has been swallowed it may be necessary to empty the stomach by aspiration and lavage. Castor oil or olive oil may be added to the water to dissolve the phenol and delay absorption: 50ml of oil may be left in the stomach.The patient should be kept warm, and pulmonary oedema, systemic acidosis, respiratory failure and circulatory failure should be treated symptomatically. Respiration may have to be assisted.


5.1. Pharmacodynamic properties

Calamine has a mild astringent action of the skin and is used as a dusting powder, cream, lotion or ointment in a variety of skin conditions.Zinc oxide has a mildly antiseptic action and is a mild astringent, it has soothing and protective properties.


5.2. Pharmacokinetic properties

No information available.


5.3. Preclinical safety data

None.


6.1. List of excipients

BentoniteSodium CitrateGlycerolPhenol Purified Water


6.2. Incompatibilities

None known.


6.3. Shelf life

100ml:

 36 months unopened

200ml:

 36 months unopened


6.4. Special precautions for storage

Store below 25°C.


6.5. Nature and contents of container

100ml:

 Glass bottle with polypropylene white 28mm cap with tamper evident band and EPE Saranex liner

200ml:

 Glass bottle with polypropylene white 28mm cap with tamper evident band and EPE Saranex liner


6.6. Special precautions for disposal and other handling

None.


7. Marketing authorisation holder

L.C.M. Limited.,Linthwaite Laboratories,Huddersfield,HD7 5QH,England.


8. Marketing authorisation number(s)

PL 12965/0003


9. Date of first authorisation/renewal of the authorisation

25/8/1993 / 15/03/2001


10. Date of revision of the text

07/11/2016

4.1 Therapeutic indications

For relief of the symptoms of mild sunburn and other minor skin conditions.

4.2 Posology and method of administration

Topical. Applied directly to the skin.

Recommended dose and dosage schedule

The product is suitable for use by adults, children and the elderly. Apply gently with a pad of cotton wool to the affected parts as required.

4.3 Contraindications

Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

Shake the bottle.For external use only.Keep all medicines away from children.

4.5 Interaction with other medicinal products and other forms of interaction

May mask x-ray pictures under certain circumstances.

4.6 Fertility, pregnancy and lactation

No evidence has been found as to the safety of the product when used during pregnancy and lactation. However, the product has been used for many years without any apparent ill effects.

4.7 Effects on ability to drive and use machines

None known.

4.8 Undesirable effects

Occasional hypersensitivity or irritant reactions.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.

Drug section

A close up image of a microscope
Clinical trial
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis (ESTEEM 1)

This study evaluated the effects of an called apremilast. Apremilast works by lowering some of the chemicals that affect psoriasis and therefore improves the symptoms of psoriasis.

2 mins
Clinical trial
Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis (GESTURE)

To demonstrate the efficacy of secukinumab versus placebo on palmoplantar psoriasis and to assess long term efficacy, safety and tolerability of secukinumab.

4 min
Clinical trial
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis. (ESTEEM 2)

This study will evaluate the effects of an experimental (being tested) study drug called apremilast.

2 min
Journals
Journal
Deroofing: a tissue-saving surgical technique for the treatment of mild to moderate hidradenitis suppurativa lesions

Objective: We sought to evaluate the efficacy and patient satisfaction of the deroofing technique for recurrent Hurley I (mild) or II (moderate) graded HS lesions at fixed locations.

1 mins
Journal
Candida infections in psoriasis and psoriatic arthritis patients treated with IL-17 inhibitors and their practical management

<p>The recognition of the central role of interleukin 17A (IL-17A) in the pathogenesis of psoriasis has led to the development of several monoclonal antibodies targeting this cytokine or its receptors for therapeutic purposes.</p>

1 min
Journal
Morbidity in patients with hidradenitis suppurativa

Objectives: To measure the impairment of life quality in patients with HS.

1 min
CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

 

 

Disclaimer

The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).